keyword
MENU ▼
Read by QxMD icon Read
search

Liver chemoembolization

keyword
https://www.readbyqxmd.com/read/28643982/-current-surgical-treatment-for-hepatocellular-carcinoma-critical-appraisal-of-current-guidelines
#1
Daniel Clerc, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
Hepatocellular carcinoma (HCC) management has evolved in the last decades. Current available treatments include interventional radiology like radiofrequency ablation, transarterial chemoembolization or Yttrium 90 radioembolization. Surgery, when possible, has been proven to be the most effective treatment in reducing the risk of long-term local recurrence. American and European societies (AASLD, EASL, respectively) guidelines for the management of HCC endorse The Barcelona Clinic Liver Cancer (BCLC) treatment allocation system...
June 14, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28640517/hepatocellular-carcinoma-in-south-america-evaluation-of-risk-factors-demographics-and-therapy
#2
Jose D Debes, Aaron J Chan, Domingo Balderramo, Luciana Kikuchi, Esteban Gonzalez Ballerga, Jhon E Prieto, Monica Tapias, Victor Idrovo, Milagros B Davalos, Fernando Cairo, Fernando J Barreyro, Sebastian Paredes, Nelia Hernandez, Karla Avendaño, Javier Diaz Ferrer, Ju Dong Yang, Enrique Carrera, Jairo A Garcia, Angelo Z Mattos, Bruno S Hirsch, Pablo T Gonçalves, Flair J Carrilho, Lewis R Roberts
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Most studies addressing the epidemiology of HCC originate from developed countries. This study reports the preliminary findings of a multinational approach to characterize HCC in South America. METHODS: We evaluated 1336 HCC patients seen at 14 centers in six South American countries using a retrospective study design with participating centers completing a template chart of patient characteristics...
June 22, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28640364/a-phase-2-study-of-the-efficacy-and-biomarker-on-the-combination-of-transarterial-chemoembolization-and-axitinib-in-the-treatment-of-inoperable-hepatocellular-carcinoma
#3
Stephen L Chan, Winnie Yeo, Frankie Mo, Anthony W H Chan, Jane Koh, Leung Li, Edwin P Hui, Charing C N Chong, Paul B S Lai, Tony S K Mok, Simon C H Yu
BACKGROUND: A surge of vascular endothelial growth factor (VEGF) after transarterial chemoembolization (TACE) may contribute to tumor progression. Axitinib is a potent antiangiogenic agent with main activity against VEGF receptors 1 to 3. To the authors' knowledge, its role in combination with TACE for the treatment of patients with inoperable hepatocellular carcinoma (HCC) is unclear. METHODS: A phase 2 clinical trial (ClinicalTrials.gov identifier NCT01352728) was conducted to evaluate the combination treatment...
June 22, 2017: Cancer
https://www.readbyqxmd.com/read/28639884/loss-of-tumor-suppressor-mir-126-contributes-to-the-development-of-hepatitis-b-virus-related-hepatocellular-carcinoma-metastasis-through-the-upregulation-of-adam9
#4
Le-Yang Xiang, Huo-Hui Ou, Xin-Cheng Liu, Zhan-Jun Chen, Xiang-Hong Li, Yu Huang, Ding-Hua Yang
Hepatocellular carcinoma is the most common histological type of primary liver cancer, which represents the second leading cause of cancer-related mortality. MiR-126 was reported to be downregulated in hepatocellular carcinoma tissues, compared with its levels in noncancerous tissues. However, baseline miR-126 expression levels in hepatitis B virus-related hepatocellular carcinoma patients who did not undergo pre-operational treatment remains unknown since hepatitis B virus infection and pre-operational transcatheter arterial chemoembolization were shown to upregulate miR-126 expression...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28638790/evolving-role-of-sorafenib-in-the-management-of-hepatocellular-carcinoma
#5
REVIEW
Ioannis A Ziogas, Georgios Tsoulfas
Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide and comes third in cancer-related mortality. Although there is a broad spectrum of treatment options to choose from, only a few patients are eligible candidates to receive a curative therapy according to their stage of disease, and thus palliative treatment is implemented in the majority of the patients suffering from liver cancer. Sorafenib, a multikinase inhibitor, is the only currently approved agent for systemic therapy in patients with advanced stage HCC and early stage liver disease...
June 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28638789/multidisciplinary-approach-of-colorectal-cancer-liver-metastases
#6
REVIEW
Giammaria Fiorentini, Donatella Sarti, Camillo Aliberti, Riccardo Carandina, Andrea Mambrini, Stefano Guadagni
Large bowel cancer is a worldwide public health challenge. More than one third of patients present an advanced stage of disease at diagnosis and the liver is the most common site of metastases. Selection criteria for early diagnosis, chemotherapy and surgery have been recently expanded. The definition of resectability remains unclear. The presence of metastases is the most significant prognostic factor. For this reason the surgical resection of hepatic metastases is the leading treatment. The most appropriate resection approach remains to be defined...
June 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28636427/liver-directed-therapy-in-metastatic-colorectal-cancer
#7
Ciara M Kelly, Nancy E Kemeny
Colorectal cancer is a significant global health issue with over 1 million cases diagnosed annually throughout the world. 15% of patients diagnosed with colorectal cancer will have liver metastases and 60% will develop liver metastases if they have metastatic disease. Oligometastatic colorectal cancer confined to the liver represents an intermediate state in the evolution of metastatic capacity that opens the opportunity for local interventions. Area's covered: The literature supports long-term survival if patients undergo liver resection of colorectal metastases...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28635404/safety-and-efficacy-of-hepasphere-50-100%C3%A2-%C3%AE-m-in-the-treatment-of-hepatocellular-carcinoma
#8
Charles Edouard Zurstrassen, Luiz Paulo De Oliveira Gireli, Chiang Jeng Tyng, Almir Galvão Vieira Bitencourt, Marcos Duarte Guimarães, Paula Nicole Vieira Barbosa, Aline Cristine Barbosa Santos Cavalcante, João Paulo Matushita Junior, Mauricio Kauark Amoedo, Felipe Jose Coimbra, Rogério Camargo Pinheiro Alves, Rubens Chojniak
AIM: To evaluate the effects of HepaSphere 50-100 μm (Merit Medical) as a doxorubicin carrier and embolization agent for the treatment of hepatocellular carcinoma (HCC). MATERIAL AND METHODS: A prospective analysis of 18 patients recruited from a national cancer center was conducted. This analysis evaluated the efficacy and safety of HepaSphere, as expressed by the treatment response rate (measured by the modified Response Evaluation Criteria in Solid Tumors, mRECIST) and by the prevalence of treatment-related adverse events, respectively...
February 14, 2017: Minimally Invasive Therapy & Allied Technologies: MITAT
https://www.readbyqxmd.com/read/28634838/superselective-transarterial-chemoembolization-as-an-alternative-to-surgery-in-symptomatic-enlarging-liver-hemangiomas
#9
İlgin Özden, Arzu Poyanlı, Yılmaz Önal, Ali Aslan Demir, Gültekin Hoş, Bülent Acunaş
BACKGROUND: Transarterial embolization of liver hemangiomas has not been considered to be consistently effective. METHODS: The charts of 25 patients who underwent superselective transarterial chemoembolization with the bleomycin-lipiodol emulsion were evaluated retrospectively. RESULTS: Twenty-two patients had abdominal pain; asymptomatic/vaguely symptomatic enlargement was the treatment indication in three patients. A single session was conducted in 17 patients, two sessions in 7 and three sessions in one...
June 20, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28634515/transarterial-chemoembolization-using-40-%C3%A2%C2%B5m-drug-eluting-beads-for-hepatocellular-carcinoma
#10
Giorgio Greco, Tommaso Cascella, Antonio Facciorusso, Roberto Nani, Rodolfo Lanocita, Carlo Morosi, Marta Vaiani, Giuseppina Calareso, Francesca G Greco, Antonio Ragnanese, Marco A Bongini, Alfonso V Marchianò, Vincenzo Mazzaferro, Carlo Spreafico
AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging...
May 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28629564/computed-tomography-perfusion-imaging-for-monitoring-transarterial-chemoembolization-of-hepatocellular-carcinoma
#11
Herman P Marquez, Amar Karalli, Holger Haubenreisser, Rishi P Mathew, Hatem Alkadhi, Torkel B Brismar, Thomas Henzler, Michael A Fischer
PURPOSE: To prospectively monitor changes in tumor perfusion of hepatocellular carcinoma (HCC) in response to doxorubicin-eluted bead based transarterial chemoembolization (DEB-TACE) using perfusion-CT (P-CT). METHODS AND MATERIALS: 24 patients (54-79 years) undergoing P-CT before and shortly after DEB-TACE of HCC were prospectively included in this dual-center study. Two readers determined arterial-liver-perfusion (ALP, mL/min/100mL), portal-venous-perfusion (PLP, mL/min/100mL) and the hepatic-perfusion-index (HPI, %) by placing matched regions-of-interests within each HCC before and after DEB-TACE...
June 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28626733/the-overall-survival-of-patients-with-hepatocellular-carcinoma-correlates-with-the-newly-defined-time-to-progression-after-transarterial-chemoembolization
#12
Tadaaki Arizumi, Kazuomi Ueshima, Mina Iwanishi, Tomohiro Minami, Hirokazu Chishina, Masashi Kono, Masahiro Takita, Norihisa Yada, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Yoriaki Komeda, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Masatoshi Kudo
AIM/BACKGROUND: The ultimate aim of any treatment for hepatocellular carcinoma (HCC) is to improve overall survival (OS); however, the clinical significance of time to progression (TTP) after transarterial chemoembolization (TACE) is unclear. This retrospective study examined the association between OS and the newly defined time to TACE progression (TTTP) to assess whether TTTP can be an alternative to OS in HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B. METHODS: Between January 2006 and December 2013, 592 patients with HCC (BCLC B1, n = 118; BCLC B2, n = 170) underwent TACE...
June 2017: Liver Cancer
https://www.readbyqxmd.com/read/28618075/surgical-treatment-for-advanced-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus
#13
REVIEW
Kazuhiko Sakamoto, Hiroaki Nagano
The Barcelona Clinic Liver Cancer (BCLC) staging system recommends administration of a tyrosine kinase inhibitor (sorafenib) as standard therapy in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). Sorafenib has been shown to prolong median overall survival (OS) by about 3 months in advanced HCC patients with PVTT (8.1 vs 4.9 months). However, its clinical effectiveness is still controversial and standard treatment with sorafenib is not established in Japan. Surgical resection is considered as a potentially curative treatment and provides an acceptable outcome for carefully selected patients...
June 15, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28611522/radiological-response-and-inflammation-scores-predict-tumour-recurrence-in-patients-treated-with-transarterial-chemoembolization-before-liver-transplantation
#14
Daniele Nicolini, Andrea Agostini, Roberto Montalti, Federico Mocchegiani, Cinzia Mincarelli, Alessandra Mandolesi, Nicola L Robertson, Roberto Candelari, Andrea Giovagnoni, Marco Vivarelli
AIM: To investigate the prognostic value of the radiological response after transarterial chemoembolization (TACE) and inflammatory markers in patients affected by hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). METHODS: We retrospectively evaluated the preoperative predictors of HCC recurrence in 70 patients treated with conventional (n = 16) or doxorubicin-eluting bead TACE (n = 54) before LT. The patient and tumour characteristics, including the static and dynamic alpha-fetoprotein, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) measurements, were recorded...
May 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28605745/current-standard-and-future-perspectives-in-non-surgical-therapy-for-hepatocellular-carcinoma
#15
Tobias Eggert, Tim F Greten
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location, or because of the patient's poor liver function, a common obstacle to HCC therapy, because HCCs almost always develop in chronically inflamed livers. SUMMARY: In recent years, many efforts have been made to improve patient survival by conducting clinical trials investigating local and systemic treatment options for patients with unresectable tumors...
June 13, 2017: Digestion
https://www.readbyqxmd.com/read/28605614/medical-management-of-hepatocellular-carcinoma
#16
Nicole E Rich, Adam C Yopp, Amit G Singal
Hepatocellular carcinoma (HCC) typically occurs in patients with advanced liver disease, so therapeutic decisions must account for the degree of underlying liver dysfunction and patient performance status in addition to tumor burden. Curative treatment options, including liver transplantation, surgical resection, and local ablative therapies, offer 5-year survival rates exceeding 60% but are restricted to patients with early-stage HCC. Surgical resection and local ablative therapies are also limited by high recurrence rates, highlighting a need for adjuvant and/or neoadjuvant therapies...
June 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28590290/huge-hepatic-fungal-inflammatory-pseudotumor-misdiagnosed-as-primary-hepatocellular-carcinoma
#17
Meng Fei Xian, Wen Tong Lan, Hui Huang, Dan Zeng, Zuo Feng Xu
Fungal inflammatory pseudotumor (FIPT) of the liver is a rare disease that may be mistaken for a malignant tumor. It is difficult to diagnose because of its nonspecific clinical and imaging features. We report the case of a 46-year-old Asian man who presented with a mass in the right upper quadrant of the abdomen. The patient had undergone transcatheter arterial chemoembolization therapy at another institution 6 months earlier, but the mass had continued to enlarge. He had no history of chronic hepatitis B, and the serum α-fetoprotein was negative...
June 6, 2017: Ultrasound Quarterly
https://www.readbyqxmd.com/read/28589145/metastasis-associated-protein-1-is-involved-in-angiogenesis-after-transarterial-chemoembolization-treatment
#18
Tao Xue, Wenming Feng, Hongbin Yu, Ming Zhu, Maoyun Fei, Ying Bao, Xiaoyi Wang, Wenxue Ma, Guiyuan Lv, Jianming Guan, Suhong Chen
BACKGROUND: Transarterial chemoembolization (TACE), a well-established treatment for unresectable hepatocellular carcinoma (HCC), blocks the arterial blood supply to the tumor, which can be short-lived as development of collateral neovessels, leading to the failure of treatment. Metastasis-associated protein 1 (MTA1) is involved in development of tumors and metastases. However, the role of MTA1 in angiogenesis is still obscure. METHODS: We detected the expression of MTA1 and hypoxia-inducible factor-1α (HIF-1α) and microvessel density (MVD) value in liver tumor tissues and tumor periphery before and after TACE treatment...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28588749/strategies-to-tackle-the-challenges-of-external-beam-radiotherapy-for-liver-tumors
#19
REVIEW
Michael I Lock, Jonathan Klein, Hans T Chung, Joseph M Herman, Edward Y Kim, William Small, Nina A Mayr, Simon S Lo
Primary and metastatic liver cancer is an increasingly common and difficult to control disease entity. Radiation offers a non-invasive treatment alternative for these patients who often have few options and a poor prognosis. However, the anatomy and aggressiveness of liver cancer poses significant challenges such as accurate localization at simulation and treatment, management of motion and appropriate selection of dose regimen. This article aims to review the options available and provide information for the practical implementation and/or improvement of liver cancer radiation programs within the context of stereotactic body radiotherapy and image-guided radiotherapy guidelines...
May 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28583650/early-response-evaluation-using-ct-perfusion-one-day-after-transarterial-chemoembolization-for-hcc-predicts-treatment-response-and-long-term-disease-control
#20
Dietmar Tamandl, Fredrik Waneck, Wolfgang Sieghart, Sylvia Unterhumer, Claus Kölblinger, Pascal Baltzer, Ahmed Ba-Ssalamah, Christian Loewe
PURPOSE: To determine the value of CT perfusion (CTP) for early response assessment after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between April 2013 and April 2015, 41 HCC (16 patients) were included in this study. CT perfusion was performed before and one day after TACE. Blood flow (BF), blood volume (BV), time to start (TTS), arterial liver perfusion (ALP), portal liver perfusion (PVP) and hepatic perfusion index (HPI) were measured...
May 2017: European Journal of Radiology
keyword
keyword
72036
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"